← Back to Screener
Day One Biopharmaceuticals, Inc. Common Stock (DAWN)
Price$21.53
Value ScoreD
Growth ScoreA
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)191.57%
Price vs S&P 500 (4W)-12.03%
VGM Score68.55
Market Capitalization$2.22B
All Metrics
Book Value / Share (Quarterly)$4.28
P/TBV (Annual)2.26x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.04
Price vs S&P 500 (YTD)126.31%
Gross Margin (TTM)89.12%
Net Profit Margin (TTM)-67.85%
EPS (TTM)$-1.04
10-Day Avg Trading Volume1.34M
EPS Excl Extra (TTM)$-1.04
EPS (Annual)$-1.04
ROI (Annual)-24.33%
Gross Margin (Annual)89.12%
Cash / Share (Quarterly)$4.28
Revenue Growth QoQ (YoY)83.92%
ROA (Last FY)-21.13%
EBITD / Share (TTM)$-1.23
ROE (5Y Avg)-40.27%
Operating Margin (TTM)-80.76%
Cash Flow / Share (Annual)$-1.04
P/B Ratio5.04x
P/B Ratio (Quarterly)2.17x
Net Income / Employee (Annual)$-602,900
EV / Revenue (TTM)12.82x
Net Interest Coverage (TTM)-0.46x
ROA (TTM)-20.69%
EPS Incl Extra (Annual)$-1.04
Current Ratio (Annual)8.02x
Quick Ratio (Quarterly)7.73x
3-Month Avg Trading Volume3.51M
52-Week Price Return193.72%
Revenue / Employee (TTM)$888,700
Tangible BV / Share (Quarterly)$4.11
P/S Ratio (Annual)14.06x
Asset Turnover (Annual)0.31x
52-Week High$21.53
EPS Excl Extra (Annual)$-1.04
CapEx CAGR (5Y)111.62%
26-Week Price Return199.03%
Quick Ratio (Annual)7.73x
13-Week Price Return74.47%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.02x
Enterprise Value$2.03B
Asset Turnover (TTM)0.30x
Revenue / Employee (Annual)$888,700
Pretax Margin (Annual)-69.10%
Cash / Share (Annual)$4.28
3-Month Return Std Dev146.28%
Net Income / Employee (TTM)$-602,900
ROE (Last FY)-24.33%
Net Interest Coverage (Annual)-1.93x
EPS Basic Excl Extra (Annual)$-1.04
Receivables Turnover (TTM)7.79x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.04
ROI (TTM)-23.43%
P/S Ratio (TTM)14.06x
Revenue / Share (Annual)$1.53
Tangible BV / Share (Annual)$4.11
Price vs S&P 500 (52W)158.83%
Year-to-Date Return131.01%
5-Day Price Return0.23%
EPS Normalized (Annual)$-1.04
ROA (5Y Avg)-37.47%
Net Profit Margin (Annual)-67.85%
Month-to-Date Return0.42%
Cash Flow / Share (TTM)$-2.29
EBITD / Share (Annual)$-1.23
Operating Margin (Annual)-80.76%
ROI (5Y Avg)-40.27%
EPS Basic Excl Extra (TTM)$-1.04
P/TBV (Quarterly)2.26x
P/B Ratio (Annual)2.17x
Inventory Turnover (TTM)3.57x
Pretax Margin (TTM)-69.10%
Book Value / Share (Annual)$4.28
Price vs S&P 500 (13W)70.85%
Beta-0.23x
Revenue / Share (TTM)$1.53
ROE (TTM)-23.43%
52-Week Low$5.63
vGradeD
gGradeA
mGradeA
vgmGradeB
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.13
2.62
2.62
2.62
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DAWNDay One Biopharmaceuticals, Inc. Common Stock | D | A | A | $21.53 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for genetically defined cancers, with initial focus on pediatric oncology, an underserved market with significant unmet medical needs. The company's lead candidate, DAY301, is an antibody-drug conjugate (ADC) that has demonstrated antitumor activity in preclinical studies.